Small Pharma Past Earnings Performance
Past criteria checks 0/6
Small Pharma's earnings have been declining at an average annual rate of -33.1%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been declining at an average rate of 187.8% per year.
Key information
-33.1%
Earnings growth rate
-26.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | -187.8% |
| Return on equity | -239.9% |
| Net Margin | n/a |
| Last Earnings Update | 31 Aug 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Small Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 23 | 0 | -19 | 11 | 11 |
| 31 May 23 | 0 | -23 | 12 | 12 |
| 28 Feb 23 | 0 | -23 | 12 | 11 |
| 30 Nov 22 | 0 | -25 | 14 | 10 |
| 31 Aug 22 | 0 | -23 | 14 | 7 |
| 31 May 22 | 0 | -20 | 12 | 6 |
| 28 Feb 22 | 0 | -22 | 11 | 5 |
| 30 Nov 21 | 0 | -21 | 9 | 4 |
| 31 Aug 21 | 0 | -18 | 7 | 3 |
| 31 May 21 | 0 | -15 | 5 | 2 |
| 28 Feb 21 | 0 | -7 | 4 | 2 |
| 28 Feb 20 | 0 | -1 | 1 | 0 |
Quality Earnings: DMT is currently unprofitable.
Growing Profit Margin: DMT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DMT is unprofitable, and losses have increased over the past 5 years at a rate of 33.1% per year.
Accelerating Growth: Unable to compare DMT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DMT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Return on Equity
High ROE: DMT has a negative Return on Equity (-239.92%), as it is currently unprofitable.